CDC42BPB Antibody

What is CDC42BPB and what cellular functions does it regulate?

CDC42BPB (CDC42 binding protein kinase beta) is a serine/threonine protein kinase that functions as an important downstream effector of CDC42 and plays a critical role in regulating cytoskeleton reorganization and cell migration . This 194 kDa protein (1711 amino acids) belongs to the AGC Ser/Thr protein kinase family and is also known as MRCKβ (myotonic dystrophy-related Cdc42-binding kinase beta) . CDC42BPB shows expression in multiple tissues, with particularly high levels in heart, brain, placenta, and lung . It has recently been associated with neurodevelopmental disorders including autism spectrum disorder (ASD) .

In concert with MYO18A and LURAP1, CDC42BPB is involved in regulating lamellar actomyosin retrograde flow that is essential for cell protrusion and migration . It also phosphorylates PPP1R12A, further contributing to its role in cytoskeletal dynamics .

How does CDC42BPB relate to immune system regulation?

CDC42, which activates CDC42BPB, is an important regulator of actin remodeling in immune cells . Studies have shown that Cdc42 is a key regulator of B cell differentiation and is required for antibody responses . Genetic ablation of Cdc42 exclusively in the B cell lineage renders mice unable to mount antibody responses, making them incapable of forming germinal centers or generating plasma B cells upon either viral infection or immunization . This immune deficiency results from multiple B cell abnormalities, including blocks in B cell development, impaired antigen-driven BCR signaling and actin remodeling, defective antigen presentation, and a severe block in plasma cell differentiation .

What disease associations have been identified for CDC42BPB?

CDC42BPB has been implicated in several pathological conditions:

• Neurodevelopmental disorders: Expression in the granule cell layer of the lateral adult cerebellum has been associated with cognitive functions and neurodevelopmental disorders including autism spectrum disorder .

• Cancer: Novel gene fusions involving CDC42BPB have been identified in cancer patients. For example, a CDC42BPB-ALK fusion was found in a patient with quadruple wild-type gastrointestinal stromal tumor (GIST) . This fusion involved CDC42BPB exon 24 and ALK exon 19, resulting in an in-frame fusion protein containing the ALK kinase domain .

• Bladder cancer: CDC42BPB has been identified as a cancer-associated gene for risk stratification in bladder cancer and may serve as a potential drug target to prevent tumor growth .

What types of CDC42BPB antibodies are available for research applications?

Several types of CDC42BPB antibodies are available for research:

• Polyclonal antibodies:

  • Example: Rabbit polyclonal antibody (31526-1-AP) validated for Western Blot (WB) and ELISA applications with human samples .

  • Typically generated against CDC42BPB fusion protein as immunogen .

• Monoclonal antibodies:

  • Example: Mouse monoclonal antibody (clone 5F12) suitable for Western Blot and ELISA applications .

  • Provides consistent results between batches with high specificity for particular epitopes .

These antibodies are available in various formats (unconjugated, conjugated) and have been validated across multiple applications including Western Blot, ELISA, immunofluorescence, and immunohistochemistry .

What validation methods ensure CDC42BPB antibody specificity?

Thorough validation of CDC42BPB antibodies should include:

• Expression validation: Testing on tissues or cell lines known to express CDC42BPB positively (heart, brain, placenta, lung) versus negative controls .

• Western Blot confirmation: Verifying that the antibody detects a protein of the expected molecular weight (194 kDa) .

• Cell line testing: Antibodies should be validated across multiple cell lines. For example, the 31526-1-AP antibody has been validated in HEK-293T cells, HeLa cells, and U-251 cells .

• Cross-reactivity assessment: Determining species reactivity and potential cross-reactivity with related proteins. Many CDC42BPB antibodies are specifically validated for human samples .

• Application-specific validation: For each intended application (WB, ELISA, IHC), specific validation data should be examined to ensure appropriate performance in that context .

What dilutions are optimal for CDC42BPB antibodies in different applications?

Optimal dilutions vary by application and specific antibody:

• Western Blot (WB):

  • For polyclonal antibody 31526-1-AP: 1:500-1:1000 dilution is recommended .

  • For monoclonal antibodies: Typically 1-5 μg/mL .

• ELISA applications:

  • Antibody concentrations may vary depending on the specific ELISA format.

  • For sandwich ELISA kits, detection antibodies are typically pre-diluted or have specific recommended dilutions .

• Immunofluorescence:

  • Optimal dilutions should be determined empirically as they may vary between antibodies .

It is recommended that each antibody should be titrated in specific testing systems to obtain optimal results, as performance can be sample-dependent .

How should CDC42BPB be detected using Western blot techniques?

For optimal Western blot detection of CDC42BPB:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors.

  • For the 194 kDa CDC42BPB, use lower percentage gels (6-8%) or gradient gels to better resolve high molecular weight proteins.

• Protein loading:

  • Load sufficient protein (typically 20-50 μg per lane) to detect CDC42BPB.

• Transfer conditions:

  • Use wet transfer with extended transfer times for high molecular weight proteins.

  • Consider adding SDS to transfer buffer to enhance transfer of large proteins.

• Antibody incubation:

  • Use recommended dilutions (1:500-1:1000 for polyclonal antibody 31526-1-AP) .

  • Incubate primary antibody overnight at 4°C for optimal results.

• Detection:

  • Use appropriate secondary antibodies matched to the host species (rabbit for 31526-1-AP, mouse for clone 5F12) .

  • Enhanced chemiluminescence detection systems are suitable for visualizing CDC42BPB.

• Positive controls:

  • Include lysates from HEK-293T cells, HeLa cells, or U-251 cells as positive controls .

What are the key considerations for CDC42BPB ELISA assay implementation?

When implementing ELISA assays for CDC42BPB:

• Sample types and preparation:

  • Compatible sample types include cell culture supernatants, plasma, and serum .

  • Two-fold dilution is recommended for serum and plasma samples .

• Assay sensitivity and range:

  • Typical detection range is 1.93 ng/ml - 150 ng/ml .

  • Sensitivity can reach 1.93 ng/ml with properly optimized conditions .

• Sample recovery considerations:

  • Recovery rates vary by sample type: serum (77.68%, range 72-86%), plasma (75.47%, range 71-83%), and cell culture media (72.24%, range 70-75%) .

• Linearity performance:

  • Dilution linearity varies by sample type:

    • Serum: 90.14% recovery at 1:2 dilution; 101.5% at 1:4 dilution

    • Plasma: 74.95% recovery at 1:2 dilution; 82.22% at 1:4 dilution

    • Cell Culture Media: 106.3% recovery at 1:2 dilution; 126.8% at 1:4 dilution

• Required equipment:

  • Microplate reader capable of measuring absorbance

  • Log-log graph paper or software for ELISA data analysis

What storage conditions maximize CDC42BPB antibody stability and performance?

For optimal stability and performance:

• Long-term storage:

  • Store at -20°C, where antibodies are typically stable for one year after shipment .

  • For unconjugated antibodies, aliquoting is generally unnecessary for -20°C storage .

• Buffer composition:

  • Many CDC42BPB antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

  • Small antibody volumes (20 μL) may contain 0.1% BSA as a stabilizer .

• Handling recommendations:

  • Prior to use, centrifuge antibody tubes at approximately 10,000 × g for 5 minutes to eliminate any particulates that could cause spurious results .

  • Allow reagents to equilibrate to room temperature before opening.

  • Avoid repeated freeze-thaw cycles that can degrade antibody quality.

• Shipping conditions:

  • Antibodies are typically shipped on blue ice or dry ice and should be transferred to proper storage immediately upon receipt .

How can LanthaScreen binding assays be optimized for CDC42BPB kinase inhibitor screening?

The LanthaScreen binding assay for CDC42BPB requires careful optimization:

• Tracer optimization:

  • Titrate Kinase Tracer 236 concentrations (typically 0.1-1000 nM) to determine optimal concentration .

  • Calculate assay window by dividing the signal in the absence of competitor by the signal in the presence of competitor (windows ≥2 typically result in high Z' values) .

• Data analysis methodology:

  • Calculate emission ratio by dividing acceptor/tracer emission (665 nm) by antibody/donor emission (615 nm) .

  • Plot [tracer] versus emission ratio for both inhibitor and control conditions .

  • For Kd determination, subtract the competitor curve from the control curve to correct for background signal .

  • Plot background-corrected emission ratios versus [tracer] and fit to one-site binding equation: Y=Bmax*X/(Kd + X) .

• Controls and references:

  • Use staurosporine as a reference control inhibitor .

  • Include DMSO control solutions to establish baseline measurements .

• Reagent preparation:

  • Use CDC42BPB at appropriate concentration (typically 0.1 to 0.5 mg/mL) .

  • Prepare proper dilutions of 1X Kinase Buffer A (50mM HEPES pH 7.5, 10 mM MgCl2, 1 mM EGTA, 0.01% Brij-35) .

How can CDC42BPB antibodies be used to investigate gene fusions in cancer research?

CDC42BPB gene fusions, such as CDC42BPB-ALK, have emerging importance in cancer research. Methods include:

• Detection approaches:

  • Immunohistochemistry: CDC42BPB-ALK fusion proteins can be detected using ALK antibodies (D5F3 clone showed strong staining in a GIST patient with CDC42BPB-ALK fusion) .

  • FISH analysis: ALK Break Apart FISH Probe kit can detect split signals indicating ALK gene breaking (detected in 90% of tumor cells in a case study) .

  • NGS verification: Next-generation sequencing can identify the precise fusion boundaries (e.g., CDC42BPB exon 24 fused to ALK exon 19) .

  • Sanger sequencing: Can be used to confirm novel fusions identified by NGS .

• Molecular characterization:

  • The CDC42BPB-ALK fusion identified in GIST contained the ALK kinase domain, suggesting its function as an oncogenic driver .

  • CDC42BPB, as a mediator of cell growth, proliferation, and apoptosis, contributes specific properties to fusion proteins that may be therapeutically relevant .

• Clinical applications:

  • Identification of CDC42BPB-ALK fusions may provide treatment options for patients with ALK inhibitors .

  • In the reported GIST case, imatinib was administered with positive outcomes, suggesting potential therapeutic approaches .

What considerations are important when studying CDC42BPB's role in neurodevelopmental disorders?

When investigating CDC42BPB in neurodevelopmental contexts:

• Expression analysis:

  • CDC42BPB shows specific expression in the granule cell layer of the lateral adult cerebellum, associated with cognitive functions .

  • Target this region specifically in tissue studies using validated antibodies.

• Model systems:

  • Consider both in vitro neuronal models and in vivo models of neurodevelopmental disorders.

  • Patient-derived samples may provide clinically relevant insights.

• Functional assays:

  • Investigate CDC42BPB's role in regulating cytoskeletal reorganization in neuronal cells.

  • Examine how CDC42BPB influences neuronal migration, axon guidance, and synapse formation.

  • Study interactions between CDC42BPB and other proteins implicated in autism spectrum disorders.

• Therapeutic implications:

  • Explore potential for CDC42BPB as a therapeutic target in neurodevelopmental disorders.

  • Use antibodies to monitor changes in CDC42BPB expression or localization in response to interventions.

What are common challenges in Western blot detection of CDC42BPB and their solutions?

Several issues may arise when detecting CDC42BPB by Western blot:

• Poor or no signal:

  • Problem: CDC42BPB is a large protein (194 kDa) that may transfer inefficiently.

  • Solution: Use wet transfer systems, extend transfer time, and consider adding SDS to transfer buffer to enhance large protein transfer.

  • Problem: Insufficient protein loading.

  • Solution: Increase protein loading to 30-50 μg per lane and use appropriate positive controls (HEK-293T, HeLa, or U-251 cells) .

• Multiple bands or wrong molecular weight:

  • Problem: Protein degradation or non-specific binding.

  • Solution: Add fresh protease inhibitors during sample preparation and increase washing stringency.

  • Problem: Post-translational modifications.

  • Solution: Consider that CDC42BPB may exhibit altered migration due to phosphorylation or other modifications.

• High background:

  • Problem: Non-specific binding or inadequate blocking.

  • Solution: Optimize blocking conditions (5% non-fat milk or BSA) and increase antibody dilution (try 1:1000 instead of 1:500) .

What factors affect ELISA performance when detecting CDC42BPB?

Key factors affecting ELISA performance include:

• Sample preparation issues:

  • Recovery rates vary by sample type (serum: 77.68%, plasma: 75.47%, cell culture media: 72.24%) .

  • Ensure samples are properly processed and stored to maintain protein integrity.

• Dilution linearity challenges:

  • Different sample types show varying linearity at different dilutions .

  • Optimize dilutions based on sample type to remain within the linear range of the assay.

• Matrix effects:

  • Components in biological samples may interfere with antibody binding.

  • Consider using assay diluents specifically formulated to minimize matrix effects.

• Technical considerations:

  • Ensure consistent temperature throughout the assay.

  • Maintain precise incubation times for all steps.

  • Use freshly prepared reagents and properly calibrated equipment.

How can researchers distinguish between CDC42BPB and its fusion proteins in experimental systems?

Distinguishing between wild-type CDC42BPB and fusion proteins requires specialized approaches:

• Antibody selection:

  • Use domain-specific antibodies that target regions either preserved or lost in the fusion protein.

  • For CDC42BPB-ALK fusions, both CDC42BPB and ALK antibodies can be used complementarily .

• Size discrimination:

  • Western blot can distinguish native CDC42BPB (194 kDa) from fusion proteins with altered molecular weights.

  • Use gradient gels for optimal resolution of high molecular weight proteins.

• Localization studies:

  • Fusion proteins may exhibit altered subcellular localization compared to wild-type CDC42BPB.

  • Use immunofluorescence with domain-specific antibodies to track localization patterns.

• Functional assays:

  • Compare kinase activity between wild-type CDC42BPB and fusion proteins.

  • Examine differential effects on downstream signaling pathways.

  • Assess changes in cytoskeletal organization and cell migration capabilities.